Quality assessment of sarcoma care in Europe and Latin America
Observational Study, for Quality Assessment, of Sarcoma As a Model to Improve Diagnosis and Clinical Care of Rare Tumors Through a European and Latin American Multidisciplinary NETWORK
This study looks at how well patients with different types of sarcoma are treated in Europe and Latin America to see if care is better at expert centers and to find ways to improve outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | Grupo Espanol de Investigacion en Sarcomas Academic / other |
| Locations | 9 sites (Buenos Aires and 8 other locations) |
| Trial ID | NCT04181970 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the quality of care for patients with soft-tissue sarcoma, gastrointestinal stromal tumors, and bone sarcoma across expert and non-expert centers. It involves both retrospective and prospective data collection, analyzing various quality indicators and patient outcomes such as survival rates and treatment efficacy. The study also includes a translational research component, utilizing tumor samples to identify biomarkers and develop preclinical models. The goal is to enhance the understanding of treatment differences and improve patient prognosis in sarcoma care.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a histological diagnosis of soft-tissue sarcoma, gastrointestinal stromal tumor, or bone sarcoma.
Not a fit: Patients with sarcomas diagnosed before January 2005 or those without available clinical and treatment information may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols and outcomes for sarcoma patients.
How similar studies have performed: Previous studies have shown positive outcomes in sarcoma management when patients are treated at expert centers, supporting the relevance of this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological diagnosis of soft-tissue sarcoma, GIST or bone sarcoma (all subtypes) from January 2005 until Juny/September 2023. * ≥ 18 years * Available clinical and treatment information Exclusion Criteria: There is no exclusion criteria
Where this trial is running
Buenos Aires and 8 other locations
- Alexander Fleming Sa — Buenos Aires, Argentina (Not_yet_recruiting)
- A C Camargo — São Paulo, Brazil (Recruiting)
- Hospital San Vicente de Paúl — Heredia, Costa Rica (Not_yet_recruiting)
- Centre Leon Berard — Lyon, France (Recruiting)
- Instituto Ortopedico Rizzoli — Bologna, Italy (Recruiting)
- Insituto Nazionale Di Tumore — Milan, Italy (Recruiting)
- Instituto Nacional de Cancerología — Mexico City, Mexico (Recruiting)
- Instituo Nacional de enfermedades Neoplásicas — Surquillo, Peru (Recruiting)
- Fundación Jiménez Díaz — Madrid, Madrid, Spain (Recruiting)
Study contacts
- Principal investigator: Javier MARTIN-BROTO, MD — Salud de Madrid
- Study coordinator: Marta Martin
- Email: martamartinruiz@atbsarc.org
- Phone: +34 910908102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.